[HTML] nature.comFull View

[HTML][HTML] Differentiation therapy for myeloid malignancies: beyond cytotoxicity

RJ Stubbins, A Karsan - Blood Cancer Journal, 2021 - nature.com
Blocked cellular differentiation is a central pathologic feature of the myeloid malignancies,
myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Treatment regimens …
被引用次数：47 相关文章

Differentiation therapy for myeloid malignancies: beyond cytotoxicity

RJ Stubbins, A Karsan - Blood cancer journal, 2021 - pubmed.ncbi.nlm.nih.gov
Blocked cellular differentiation is a central pathologic feature of the myeloid malignancies,
myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Treatment regimens …

Differentiation therapy for myeloid malignancies: beyond cytotoxicity

RJ Stubbins, K Aly - Blood Cancer Journal, 2021 - search.proquest.com
Blocked cellular differentiation is a central pathologic feature of the myeloid malignancies,
myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Treatment regimens …
[HTML] nih.gov

[HTML][HTML] Differentiation therapy for myeloid malignancies: beyond cytotoxicity

RJ Stubbins, A Karsan - Blood Cancer Journal, 2021 - ncbi.nlm.nih.gov
Blocked cellular differentiation is a central pathologic feature of the myeloid malignancies,
myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Treatment regimens …

Differentiation therapy for myeloid malignancies: beyond cytotoxicity.

RJ Stubbins, A Karsan - Blood Cancer Journal, 2021 - search.ebscohost.com
Blocked cellular differentiation is a central pathologic feature of the myeloid malignancies,
myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Treatment regimens …

Differentiation therapy for myeloid malignancies: beyond cytotoxicity.

RJ Stubbins, A Karsan - Blood Cancer Journal, 2021 - europepmc.org
Blocked cellular differentiation is a central pathologic feature of the myeloid malignancies,
myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Treatment regimens …